Long Term Outcomes of Liver Transplantation in the Direct-Acting Antiviral Era of Hepatitis C
Poster May 09, 2018
Anwar Khan, Angel Alsina MD, Alexia Athienitis PhD, John Trendowski BS, Alejandro Delgado BS, Arun Konakanchi, Jacentha Buggs MD, Elizabeth Fallon PA-C, Erin Parkinson ARNP, Christopher Albers MD, Nyingi Kemmer MD
There are no reports of long term outcomes of Hepatitis C (HCV) liver transplant (LTx) recipients in the direct-acting antiviral (DAA) era. We aimed to examine impact of DAA’s on survival, examine the populations at risk, cure rates, and long term outcomes.
To our knowledge, this is the first long term outcomes report from a liver transplant center in Florida and the first one to be performed in organ transplantation at Tampa General Hospital. It is certainly the first time that the liver transplant program has analyzed the outcome of all consecutive patients, long term.
We hypothesized that survival of Hepatitis C patients has improved over the last decade, last eras of transplantation, and since creation of specialized Hepatitis C Clinic and availability of direct-acting antiviral (DAA) agents.
Retrospective analysis of 469 HCV LTx, between Dec 1996 and July 25, 2015 (from 1,368 LTx). These were divided in 4 eras: 1 (’97-2001), 2 (2002-06), 3 (2007-10), and Era 4 (2011-15, corresponding to DAA’s). All DAA treatments in this study were post LTx. Kaplan Meier methodology, Log Rank and Chi square were utilized.
Cohorts were selected according to defined time periods or major programmatic changes, personnel, or specialized programs. Additional hypothesis were formulated while examining the impact of the DAA era. We examined which populations had the opportunity to receive DAA’s and hypothesized further that older eras had little benefit from DAA’s. We also examined cure and treatment rates for each era.
The lower 8% mortality in Era 3 prior to 2011 allowed patients the access to highly curative DAA therapies.
Era 4 more than doubled the number of patients treated with DAA’s over Era 3. Era’s 3 and 4 more than tripled the number of patients treated.
Over 90% of the patients in Eras 3 and 4 were alive and available for treatment.
DAA’s had a significant impact on HCV patients in our program while patients in Era 1 and 2 succumbed from hepatitis C complications.
From 2007 forward, progress in HCV outcomes was noted, contributed by DAA and HCV cures. Those transplanted more than 10 years ago were highly excluded from the DAA era. Our three year results suggest that HCV patients now outperform most other populations of transplant patients.
Young Adult Women’s Relationship Status and HPV Risk Perceptions: A Barrier to HPV Vaccination?Poster
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE
The Role of K13 in Artemisinin ResistancePoster
Plasmodium falciparum is evolving resistance to Artemisinin Combination Therapy. The gene with the strongest association with resistance is K13. K13 is an ortholog of the well characterized transcriptional regulator Keap1. In this work we transcriptionally characterized a mutant with a transposon inserted in the K13 promoter region which results in dysregulation of K13 at 2 points of the intraerythrocytic cycle of the life-cycle to identify the processes regulated by K13.READ MORE